Erythropoietin administration for prevention of cardiac surgery-associated acute kidney injury: A meta-analysis of randomized controlled trials

European Journal of Cardio-thoracic Surgery

Volumn 48, Issue 1, 2015, Pages 32-39

  Tie, Hong Tao ^a   Luo, Ming Zhu ^b   Lin, Dan ^b   Zhang, Min ^a   Wan, Jing Yuan ^b   Wu, Qing Chen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Acute kidney injury; Cardiac surgery; Erythropoietin; Meta analysis

Indexed keywords

CREATININE; ERYTHROPOIETIN; PLACEBO;

ACUTE KIDNEY FAILURE; ANEMIA; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; HEART ARRHYTHMIA; HEART SURGERY; HEART VALVE SURGERY; HUMAN; INCIDENCE; LENGTH OF STAY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RISK FACTOR; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; AGED; CARDIOPULMONARY BYPASS; FEMALE; MALE; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84936880209     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu378     Document Type: Review

References (34)

1. Brown JR, Kramer RS, Coca SG, Parikh CR. Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg 2010;90: 1142-8.
2. Englberger L, Suri RM, Connolly HM, Li Z, Abel MD, Greason KL et al. Increased risk of acute kidney injury in patients undergoing tricuspid valve surgery. Eur J Cardiothorac Surg 2013;43:993-9.
3. Parolari A, Pesce LL, Pacini D, Mazzanti V, Salis S, Sciacovelli C et al. Risk factors for perioperative acute kidney injury after adult cardiac surgery: role of perioperative management. Ann Thorac Surg 2012;93:584-91.
4. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999;14:1158-62.
5. Coleman MD, Shaefi S, Sladen RN. Preventing acute kidney injury after cardiac surgery. Curr Opin Anaesthesiol 2011;24:70-6.
6. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-70.
7. Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008;23:1970-4.
8. Mao H, Katz N, Ariyanon W, Blanca-Martos L, Adỳbelli Z, Giuliani A et al. Cardiac Surgery-Associated Acute Kidney Injury. Cardiorenal Medicine 2013;3:178-99.
9. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney injury: a relevant complication after cardiac surgery. Ann Thorac Surg 2011;92:1539-47.
10. Moss E, Lamarche Y. Acute kidney injury following cardiac surgery: prevention, diagnosis, and management. In: Momir Polenakovic (ed). Renal Failure -The Facts. InTech (2012). doi: 10.5772/37434.
11. Argalious M, Motta P, Khandwala F, Samuel S, Koch CG, Gillinov AM et al. 'Renal dose' dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 2005;33:1327-32.
12. Ristikankare A, Kuitunen T, Kuitunen A, Uotila L, Vento A, Suojaranta-Ylinen R et al. Lack of renoprotective effect of I.V. n-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006;97:611-6.
13. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009;18:15-20.
14. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl 2007;107:S10-5.
15. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care 2011;1:1-10.
16. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012;13:132.
17. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care 2013;17:R254.
18. Oh SW, Chin HJ, Chae DW, Na KY. Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci 2012;27:506-11.
19. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009;30:253-60.
20. Tasanarong A, Duangchana S, Sumransurp S, Homvises B, Satdhabudha O. Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial. BMC Nephrol 2013;14:136.
21. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011;115:929-37.
22. Bellomo R, Auriemma S, Fabbri A, D'Onofrio A, Katz N, McCullough PA et al. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs 2008;31:166-78.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
25. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann InternMed 2001;135:982-9.
26. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-60.
28. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115.
29. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010;77: 1020-30.
30. Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A et al. Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin Exp Pharmacol Physiol 2010;37:1139-46.
31. Warren JS, Zhao Y, Yung R, Desai A. Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;57:424-33.
32. Mimic-Oka J, Simic T, Djukanovic L. Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patients. Ren Fail 2002;24:77-87.
33. Hu L, Yang C, Zhao T, Xu M, Tang Q, Yang B et al. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 2012;176:260-6.
34. Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care 2011;39:356-72.